View Older Stories View More Recent Stories

Dec 8, 2020 08:00AM Seagen Highlights TUKYSA® (tucatinib) Data in Breast Cancer at Virtual 2020 San Antonio Breast Cancer Symposium
Dec 7, 2020 10:00AM Seagen Announces Multiple ADCETRIS® (brentuximab vedotin) Presentations at the 2020 ASH Annual Meeting
Nov 9, 2020 08:00AM Seagen Highlights Immuno-Oncology Data from Broad Portfolio During SITC Virtual Annual Meeting 2020
Nov 5, 2020 08:00AM Seagen Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Upcoming ASH Annual Meeting
Nov 2, 2020 08:00AM Seagen to Host Virtual R&D Day on November 16, 2020
Oct 29, 2020 04:02PM Seagen Reports Third Quarter 2020 Financial Results
Oct 28, 2020 08:00AM Seagen Announces Closing of $1.0 Billion Stock Sale to Merck
Oct 27, 2020 06:45AM Merck Announces Third-Quarter 2020 Financial Results
Oct 13, 2020 08:00AM Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2020 Financial Results on October 29, 2020
Oct 12, 2020 06:46AM Seagen (SGEN) and Astellas Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV in Advanced UC
Oct 12, 2020 06:45AM Astellas and Seagen Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer
Oct 12, 2020 06:45AM Seagen and Astellas Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer
Oct 8, 2020 08:00AM Seattle Genetics, Inc. Announces Corporate Name Change to Seagen Inc.
Sep 21, 2020 10:20AM Seattle Genetics (SGEN) and Genmab (GMAB) Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO
Sep 21, 2020 10:20AM Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
Sep 21, 2020 10:20AM Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
Sep 18, 2020 06:46AM Seattle Genetics (SGEN), Astellas Report PADCEV (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial
Sep 18, 2020 06:45AM Seattle Genetics and Astellas Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cance
Sep 18, 2020 06:45AM Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cance
Sep 14, 2020 06:45AM Seattle Genetics (SGEN) and Merck (MRK) Announce Two Strategic Oncology Collaborations; Merck to Invest $1B
Sep 14, 2020 06:45AM Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations
Sep 3, 2020 08:00AM Seattle Genetics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
Aug 27, 2020 08:11AM Seattle Genetics (SGEN) to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline (GSK) Following EC Approval of BLENREP
Aug 27, 2020 08:10AM Seattle Genetics to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline Following European Commission Approval of BLENREP (belantamab mafodotin)
Aug 27, 2020 08:00AM Seattle Genetics Highlights Data from Broad Oncology Portfolio During ESMO Virtual Congress 2020
Aug 18, 2020 08:00AM Seattle Genetics Appoints Ted W. Love, M.D., to Board of Directors
Aug 12, 2020 08:00AM Seattle Genetics Announces TUKYSA® (tucatinib) Approved Within Months for All Countries Participating in FDA’s Project Orbis Initiative
Aug 6, 2020 08:23AM Seattle Genetics (SGEN) Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline Triggered by BLENREP FDA Approval
Aug 6, 2020 08:00AM Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline Triggered by BLENREP (belantamab mafodotin-blmf) FDA Approval
Jul 30, 2020 04:02PM Seattle Genetics Reports Second Quarter 2020 Financial Results
Jul 9, 2020 08:00AM Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2020 Financial Results on July 30, 2020
Jun 29, 2020 04:31PM Seattle Genetics (SGEN) Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Jun 29, 2020 04:30PM Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Jun 18, 2020 08:02AM Seattle Genetics (SGEN) Announces Initiation of Phase 1 Clinical Trials for Two Novel Antibody-Based Drug Candidates
Jun 18, 2020 08:00AM Seattle Genetics Announces Initiation of Phase 1 Clinical Trials for Two Novel Antibody-Based Drug Candidates
Jun 3, 2020 08:00AM Seattle Genetics to Present at Goldman Sachs 41st Annual Global Healthcare Conference
May 29, 2020 08:08AM Seattle Genetics (SGEN) Announces Positive Results from Exploratory Analyses of HER2CLIMB for TUKYSA in Brain Metastases Patients With HER2-Positive Breast Cancer
May 29, 2020 08:00AM Seattle Genetics Announces Positive Results from Exploratory Analyses of HER2CLIMB for TUKYSA™ (tucatinib) in Brain Metastases Patients With HER2-Positive Breast Cancer
May 18, 2020 08:00AM Seattle Genetics Antibody-Drug Conjugate Innovation and Targeted Therapy Programs to be Featured at the AACR Virtual Annual Meeting II on June 22-24, 2020
May 14, 2020 08:06AM Seattle Genetics (SGEN) Announces ADCETRIS Receives EC Approval for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma
May 14, 2020 08:00AM Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma
May 13, 2020 05:14PM Seattle Genetics (SGEN) Highlights Data from Expanding Oncology Portfolio During Virtual Scientific Program of the 2020 ASCO
May 13, 2020 05:12PM Seattle Genetics Highlights Data from Expanding Oncology Portfolio During Virtual Scientific Program of the 2020 ASCO Annual Meeting
May 12, 2020 08:02AM Seattle Genetics (SGEN) Announces the Approval of TUKYSA in Switzerland for Treatment of Patients with Metastatic HER2-Positive Breast Cancer
May 12, 2020 08:00AM Seattle Genetics Announces the Approval of TUKYSA™ (tucatinib) in Switzerland for the Treatment of Patients with Metastatic HER2-Positive Breast Cancer
May 5, 2020 08:00AM Seattle Genetics to Present at the BofA Securities Virtual Health Care Conference 2020
Apr 30, 2020 04:02PM Seattle Genetics Reports First Quarter 2020 Financial Results
Apr 24, 2020 08:00AM Seattle Genetics Announces Change to Virtual Format for 2020 Annual Meeting
Apr 17, 2020 02:28PM Seattle Genetics (SGEN) Confirms FDA Approval of TUKYSA for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer
Apr 17, 2020 02:27PM Seattle Genetics Announces U.S. FDA Approval of TUKYSA™ (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer
View More Recent Stories View Older Stories